Establishment Labs (NASDAQ:ESTA) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Establishment Labs (NASDAQ:ESTA) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

ESTA has been the topic of a number of other reports. Mizuho increased their price objective on shares of Establishment Labs from $58.00 to $70.00 and gave the company an “outperform” rating in a research note on Wednesday, July 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Establishment Labs in a research note on Wednesday, October 8th. Canaccord Genuity Group initiated coverage on shares of Establishment Labs in a research note on Wednesday, August 20th. They set a “buy” rating and a $60.00 price objective on the stock. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a research note on Tuesday, October 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $48.00 price objective on shares of Establishment Labs in a research note on Friday, June 13th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Establishment Labs currently has a consensus rating of “Moderate Buy” and an average price target of $56.50.

Establishment Labs Price Performance

Shares of ESTA stock opened at $41.16 on Friday. The company has a debt-to-equity ratio of 9.71, a current ratio of 2.84 and a quick ratio of 1.67. The company has a market capitalization of $1.19 billion, a P/E ratio of -13.50 and a beta of 0.85. The company’s 50-day simple moving average is $39.57 and its two-hundred day simple moving average is $38.01. Establishment Labs has a one year low of $26.56 and a one year high of $50.85.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Thursday, August 7th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). The company had revenue of $51.30 million during the quarter, compared to the consensus estimate of $50.80 million. Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.Establishment Labs’s revenue was up 16.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.62) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Establishment Labs will post -2.41 EPS for the current year.

Institutional Investors Weigh In On Establishment Labs

Several institutional investors have recently bought and sold shares of the company. Elevation Point Wealth Partners LLC purchased a new position in shares of Establishment Labs in the first quarter worth $207,000. Guided Capital Wealth Management LLC purchased a new position in shares of Establishment Labs in the first quarter worth $1,794,000. New York State Common Retirement Fund purchased a new position in shares of Establishment Labs in the first quarter worth $894,000. Rice Hall James & Associates LLC raised its holdings in shares of Establishment Labs by 7.4% in the first quarter. Rice Hall James & Associates LLC now owns 827,423 shares of the company’s stock worth $33,763,000 after buying an additional 56,756 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd purchased a new position in shares of Establishment Labs in the first quarter worth $81,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.